Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T

Thu Apr 4, 2013 9:00am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130404:nGNXUXMHJa

ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the
leading developer of patient-specific expanded multicellular therapies for the treatment of severe
chronic cardiovascular diseases, today announced that the first patients have been enrolled in the
ixCELL-DCM clinical trial. This Phase 2b study is currently underway in the United States to
assess the efficacy and safety of ixmyelocel-T in the treatment of patients with advanced heart
failure due to ischemic dilated cardiomyopathy (ischemic DCM).

"Enrolling the first patients in the ixCELL-DCM trial is an important milestone in our effort to
bring this potential new treatment for advanced heart failure to thousands of people who might
benefit from it," said David Recker, M.D., acting chief medical officer at Aastrom Biosciences.

The ixCELL-DCM trial is a randomized, double-blind, placebo-controlled phase 2b study with a
planned enrollment of 108 patients at approximately 30 sites in the U.S. In the study,
ixmyelocel-T will be administered via catheter-based injections to patients with advanced heart
failure due to ischemic DCM. The primary endpoint of the trial will be the average number of
events per patient, which include all-cause mortality, all-cause hospitalizations or unplanned
hospital visits to treat worsening heart failure. Patients will be followed for a total of 12
months.

"We recently refocused our clinical program on the development of ixmyelocel-T for the treatment
of dilated cardiomyopathy and other rare disease indications and are delighted to enroll our first
patients in the ixCELL-DCM study," said Nick Colangelo, president and chief executive officer at
Aastrom Biosciences. "We have increased the number of sites participating in this study which will
help us build momentum in patient enrollment and complete the trial on schedule."

For more information on ischemic DCM and ixmyelocel-T, visit
http://www.aastrom.com/cardiovascular-disease-patients/living-with-dcm-video/
http://www.globenewswire.com/newsroom/ctr?d=10027326&l=5&u=http%3A%2F%2Fwww.aastrom.com%2Fcardiovascular-disease-patients%2Fliving-with-dcm-video%2F


About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies
for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's
proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase
2b clinical trial in patients with ischemic dilated cardiomyopathy. For more information, please
visit Aastrom's website at www.aastrom.com
http://www.globenewswire.com/newsroom/ctr?d=10027326&l=7&a=www.aastrom.com&u=http%3A%2F%2Fwww.aastrom.com%2F
.

The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
http://www.globenewswire.com/newsroom/ctr?d=10027326&l=8&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D3663


This document contains forward-looking statements, including, without limitation, statements
concerning clinical trial plans and progress, objectives and expectations, clinical activity
timing, intended product development, the performance and contribution of certain individuals and
expected timing of collecting and analyzing treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made through the use of words or
phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional verbs such as "will," "would,"
"should," "potential," "could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties associated with clinical trial and
product development activities, regulatory approval requirements, competitive developments, and
the availability of resources and the allocation of resources among different potential uses.
These and other significant factors are discussed in greater detail in Aastrom's Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward-looking statements reflect management's current views and Aastrom does
not undertake to update any of these forward-looking statements to reflect a change in its views
or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Media contact
         Andrea Coan
         Berry & Company
         acoan@berrypr.com
         (212) 253-8881
         
         Investor contact
         Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.